256 related articles for article (PubMed ID: 22813402)
1. Tumor stromal vascular endothelial growth factor A is predictive of poor outcome in inflammatory breast cancer.
Arias-Pulido H; Chaher N; Gong Y; Qualls C; Vargas J; Royce M
BMC Cancer; 2012 Jul; 12():298. PubMed ID: 22813402
[TBL] [Abstract][Full Text] [Related]
2. Identifying the impact of inflammatory breast cancer on survival: a retrospective multi-center cohort study.
Diessner J; Van Ewijk R; Weiss CR; Janni W; Wischnewsky MB; Kreienberg R; Hancke K; Blettner M; Wöckel A; Schwentner L
Arch Gynecol Obstet; 2015 Sep; 292(3):655-64. PubMed ID: 25814296
[TBL] [Abstract][Full Text] [Related]
3. The prognostic and predictive value of mRNA expression of vascular endothelial growth factor family members in breast cancer: a study in primary tumors of high-risk early breast cancer patients participating in a randomized Hellenic Cooperative Oncology Group trial.
Linardou H; Kalogeras KT; Kronenwett R; Kouvatseas G; Wirtz RM; Zagouri F; Gogas H; Christodoulou C; Koutras AK; Samantas E; Pectasides D; Bafaloukos D; Fountzilas G
Breast Cancer Res; 2012 Nov; 14(6):R145. PubMed ID: 23146280
[TBL] [Abstract][Full Text] [Related]
4. The combined presence of CD20 + B cells and PD-L1 + tumor-infiltrating lymphocytes in inflammatory breast cancer is prognostic of improved patient outcome.
Arias-Pulido H; Cimino-Mathews A; Chaher N; Qualls C; Joste N; Colpaert C; Marotti JD; Foisey M; Prossnitz ER; Emens LA; Fiering S
Breast Cancer Res Treat; 2018 Sep; 171(2):273-282. PubMed ID: 29858752
[TBL] [Abstract][Full Text] [Related]
5. Quantitative hormone receptor (HR) expression and gene expression analysis in HR+ inflammatory breast cancer (IBC) vs non-IBC.
Iwase T; Harano K; Masuda H; Kida K; Hess KR; Wang Y; Dirix L; Van Laere SJ; Lucci A; Krishnamurthy S; Woodward WA; Layman RM; Bertucci F; Ueno NT
BMC Cancer; 2020 May; 20(1):430. PubMed ID: 32423453
[TBL] [Abstract][Full Text] [Related]
6. Vascular endothelial growth factor receptor expression as a prognostic marker for survival in colorectal cancer.
Okita NT; Yamada Y; Takahari D; Hirashima Y; Matsubara J; Kato K; Hamaguchi T; Shirao K; Shimada Y; Taniguchi H; Shimoda T
Jpn J Clin Oncol; 2009 Sep; 39(9):595-600. PubMed ID: 19535387
[TBL] [Abstract][Full Text] [Related]
7. The relationship of the angiogenesis regulators VEGF-A, VEGF-R1 and VEGF-R2 to p53 status and prognostic factors in epithelial ovarian carcinoma in FIGO-stages I-II.
Skirnisdottir I; Seidal T; Åkerud H
Int J Oncol; 2016 Mar; 48(3):998-1006. PubMed ID: 26783205
[TBL] [Abstract][Full Text] [Related]
8. Chemotherapy response and survival of inflammatory breast cancer by hormone receptor- and HER2-defined molecular subtypes approximation: an analysis from the National Cancer Database.
Liu J; Chen K; Jiang W; Mao K; Li S; Kim MJ; Liu Q; Jacobs LK
J Cancer Res Clin Oncol; 2017 Jan; 143(1):161-168. PubMed ID: 27704268
[TBL] [Abstract][Full Text] [Related]
9. Influence of Biologic Subtype of Inflammatory Breast Cancer on Response to Neoadjuvant Therapy and Cancer Outcomes.
Hieken TJ; Murphy BL; Boughey JC; Degnim AC; Glazebrook KN; Hoskin TL
Clin Breast Cancer; 2018 Aug; 18(4):e501-e506. PubMed ID: 29089281
[TBL] [Abstract][Full Text] [Related]
10. Metastatic behavior and overall survival according to breast cancer subtypes in stage IV inflammatory breast cancer.
van Uden DJP; van Maaren MC; Strobbe LJA; Bult P; van der Hoeven JJ; Siesling S; de Wilt JHW; Blanken-Peeters CFJM
Breast Cancer Res; 2019 Oct; 21(1):113. PubMed ID: 31623649
[TBL] [Abstract][Full Text] [Related]
11. Comparison of survival in non-metastatic inflammatory and other T4 breast cancers: a SEER population-based analysis.
Jiao D; Zhang J; Zhu J; Guo X; Yang Y; Xiao H; Liu Z
BMC Cancer; 2021 Feb; 21(1):138. PubMed ID: 33549037
[TBL] [Abstract][Full Text] [Related]
12. Shorter survival-times following adjuvant endocrine therapy in oestrogen- and progesterone-receptor positive breast cancer overexpressing HER2 and/or with an increased expression of vascular endothelial growth factor.
Linderholm B; Bergqvist J; Hellborg H; Johansson U; Linderholm M; von Schoultz E; Elmberger G; Skoog L; Bergh J
Med Oncol; 2009 Dec; 26(4):480-90. PubMed ID: 19130322
[TBL] [Abstract][Full Text] [Related]
13. Prognostic impact of human epidermal growth factor-like receptor 2 and hormone receptor status in inflammatory breast cancer (IBC): analysis of 2,014 IBC patient cases from the California Cancer Registry.
Zell JA; Tsang WY; Taylor TH; Mehta RS; Anton-Culver H
Breast Cancer Res; 2009; 11(1):R9. PubMed ID: 19228416
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical Expressions of Senescence-Associated Secretory Phenotype and Its Association With Immune Microenvironments and Clinicopathological Factors in Invasive Breast Cancer.
Park MH; Choi JE; Kim JR; Bae YK
Pathol Oncol Res; 2021; 27():1609795. PubMed ID: 34267603
[TBL] [Abstract][Full Text] [Related]
15. Impact of vascular endothelial growth factor receptor 1, 2, and 3 expression on the outcome of patients with gastric cancer.
Hirashima Y; Yamada Y; Matsubara J; Takahari D; Okita N; Takashima A; Kato K; Hamaguchi T; Shirao K; Shimada Y; Taniguchi H; Shimoda T
Cancer Sci; 2009 Feb; 100(2):310-5. PubMed ID: 19068081
[TBL] [Abstract][Full Text] [Related]
16. The association between vascular endothelial growth factor expression in invasive breast cancer and survival varies with intrinsic subtypes and use of adjuvant systemic therapy: results from the Nurses' Health Study.
Liu Y; Tamimi RM; Collins LC; Schnitt SJ; Gilmore HL; Connolly JL; Colditz GA
Breast Cancer Res Treat; 2011 Aug; 129(1):175-84. PubMed ID: 21390493
[TBL] [Abstract][Full Text] [Related]
17. Discrepancy between FDG-PET/CT and contrast-enhanced CT in the staging of patients with inflammatory breast cancer: implications for treatment planning.
Jacene HA; DiPiro PJ; Bellon J; Hu J; Cheng SC; Warren L; Schlosnagle E; Nakhlis F; Rosenbluth JM; Yeh E; Overmoyer B
Breast Cancer Res Treat; 2020 Jun; 181(2):383-390. PubMed ID: 32318957
[TBL] [Abstract][Full Text] [Related]
18. Differential effects of CD20+ B cells and PD-L1+ immune cells on pathologic complete response and outcome: comparison between inflammatory breast cancer and locally advanced breast cancer patients.
Arias-Pulido H; Cimino-Mathews AM; Chaher N; Qualls CR; Joste N; Colpaert C; Marotti JD; Chamberlin MD; Foisey MG; Prossnitz ER; Emens LA; Fiering S
Breast Cancer Res Treat; 2021 Dec; 190(3):477-489. PubMed ID: 34542773
[TBL] [Abstract][Full Text] [Related]
19. The Impact of Residual Disease After Preoperative Systemic Therapy on Clinical Outcomes in Patients with Inflammatory Breast Cancer.
Nakhlis F; Regan MM; Warren LE; Bellon JR; Hirshfield-Bartek J; Duggan MM; Dominici LS; Golshan M; Jacene HA; Yeh ED; Mullaney EE; Overmoyer B
Ann Surg Oncol; 2017 Sep; 24(9):2563-2569. PubMed ID: 28560598
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of lymphangiogenic factors, vascular endothelial growth factor D and E-cadherin in distinguishing inflammatory from locally advanced breast cancer.
Levine PH; Portera CC; Hoffman HJ; Yang SX; Takikita M; Duong QN; Hewitt SM; Swain SM
Clin Breast Cancer; 2012 Aug; 12(4):232-9. PubMed ID: 22694825
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]